Stock Alert: Baudax Bio (BXRX)

(RTTNews) - Baudax Bio Inc. (BXRX) is all set to know the FDA decision on its IV injectable form of Meloxicam, a non-opioid candidate for pain reduction, on February 20, 2020.

The intravenous Meloxicam had been twice rejected by the FDA - in May 2018 and in March 2019.

Baudax Bio is a spinoff from Recro Pharma Inc (REPH), and it began trading on the NASDAQ Capital Market on November 22, 2019.

As of December 31, 2019, the Company had cash and cash equivalents of $17.7 million.

BXRX has thus far hit a low of $3.57 and a high of $9.60. The stock closed Thursday's (Feb.13, 2020) trading at $8.55, up 3.01%. In after-hours, it was down 0.58% at $8.50.